Top Markets
#1 Nesa Nesa +720.45%
#2 EXOD EXOD +22.78%
#3 MetaDAO MetaDAO +14.20%
#4 Venom Venom +10.59%
#5 Pons Pons +9.49%
#6 PondCoin PondCoin +8.69%
#7 Status Status +8.08%
#8 Wrapped NXM Wrapped NXM +8.03%
#9 Prom Prom +7.99%
#10 Ontology Gas Ontology Gas +7.17%
Coin of the day
Nesa Nesa
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Hyloris Pharmaceuticals S.A. Hyloris Pharmaceuticals S.A.

Hyloris Pharmaceuticals S.A.

HYL
Kedudukan dalam Saham #19946
Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and... Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and bringing to market pharmaceutical products designed to fulfill critical unmet medical needs. The company's focus areas include cardiovascular health, oncology, women's health, and other significant therapeutic domains. Its cardiovascular portfolio features treatments for conditions such as atrial fibrillation, acute coronary syndrome, advanced and congestive heart failure, and coronary heart disease. Beyond this, Hyloris addresses a diverse range of other ailments, including post-operative pain management, dental indications, severe and recurring vulvovaginal candidiasis, specific cancers (like acute myeloid leukemia and small cell lung cancer), interstitial cystitis/painful bladder syndrome (IC/PBS), attention deficit hyperactivity disorder (ADHD), and various viral infections. Established in 2012, Hyloris Pharmaceuticals SA is headquartered in Liège, Belgium.
Harga Saham
$5.22
Disegerakkan terakhir: 2026-08-25
Modal Pasaran
$146.14M
Perubahan (1 hari)
-1.35%
Perubahan (1 tahun)
-32.08%
Negara
BE
Perdagangan Hyloris Pharmaceuticals S.A. (HYL)

Kategori

Healthcare
Pendapatan untuk Hyloris Pharmaceuticals S.A. (HYL)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Hyloris Pharmaceuticals S.A., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Hyloris Pharmaceuticals S.A. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH